{"pub": "marketwatch", "url": "https://marketwatch.com/articles/biogen-stock-could-have-run-up-too-far-on-alzheimers-drug-revival-51571759303", "downloaded_at": "2019-10-22 16:07:00.440748+00:00", "title": "Biogen Stock Could Have Run Up Too Far on Alzheimer\u2019s Drug Revival", "language": "en", "text": "Biogen triggered a rally in its shares Tuesday morning with news of the revival of its failed Alzheimer\u2019s drug aducanumab, but the early-morning run-up may be overdone.\n\nShares of Biogen (ticker: BIIB) were up as high as 37% in early trading after the biotech company seemingly erased its signal failure of the year\u2014one that has weighed not just on Biogen, but on the entire sector. The company said that despite canceling a Phase 3 trial in March when it appeared that the drug wasn\u2019t working, it now plans to submit aducanumab...", "description": "Shares were up as high as 37% in early trading after the biotech company seemingly erased its signal failure of the year. Some analysts are more cautious.", "authors": ["Josh Nathan-Kazis"], "top_image": "https://asset.barrons.com/public/resources/images/ON-DH057_biogen_OR_20191022111830.jpg", "published_at": "2019-10-22"}